Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer

Sponsor
Affiliated Hospital of Qinghai University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05125432
Collaborator
(none)
59
Enrollment
1
Location
1
Arm
24.1
Anticipated Duration (Months)
2.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Purpose:Acupuncture for arthralgia induced by aromatase inhibitors in patients with breast cancer associated with screening of SNPs.

Condition or DiseaseIntervention/TreatmentPhase
  • Device: Acupuncture group
N/A

Detailed Description

Aromatase inhibitor-induced arthralgia (AIA) is the most common side effect of aromatase inhibitors (AIs) used in breast cancer , may cause poor adherence to AIs. Studies have shown that acupuncture has a certain therapeutic effect on AIA in breast cancer. In this study, acupuncture was used to relieve the symptoms of arthralgia in patients, and the efficacy of acupuncture was observed by using relevant scales. Currently, studies have shown that AIA in breast cancer patients is related to some biological factors.

At the same time, we collected peripheral blood samples of patients, combined with the reported relevant literature, screened out the single nucleotide polymorphisms(SNP) related to AIA and to guide acupuncture treatment of aromatase Inhibitors induced arthralgia, balance the toxicity of endocrine therapy, and improve compliance and effectiveness.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
59 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer
Anticipated Study Start Date :
Nov 25, 2021
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
Nov 30, 2023

Arms and Interventions

ArmIntervention/Treatment
Experimental: Acupuncture group

Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.

Device: Acupuncture group
Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.

Outcome Measures

Primary Outcome Measures

  1. Changes in arthralgia scores were measured by the BPI [52 weeks]

    Changes in arthralgia scores were measured by the Brief Pain Inventory (BPI) before and after acupuncture treatment.

Secondary Outcome Measures

  1. Changes in arthralgia scores were measured by the WOMAC scales [52 weeks]

    Changes in arthralgia scores were measured by the McMasters College Osteoarthritis Index Score (WOMAC) scales before and after acupuncture treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. History of stage I-III breast cancer and free of disease by clinical examination;Currently receiving aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) treatment;

  2. AI-assisted treatment has lasted for more than one month, and there are obvious symptoms of arthralgia ;

  3. Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent);

  4. Eastern Cooperative Oncology Group (ECOG) score of physical condition (0-1);

  5. Patients with previous local recurrence were eligible, but not patients with distant metastasis;

  6. The basic indexes were consistent, and the blood routine and ECG were normal.

Exclusion Criteria:
  1. Patients with needle phobia;

  2. Low platelet count (<50000); comorbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels <10 g/dl and haematocrit <30; anaemia on active pharmacological treatment orreceiving blood transfusion or steroids;

  3. Lymphoedematous of limbs;

  4. Patients have a history of acupuncture treatment for 6 months;

  5. Patients were reluctant to participate in the study;

  6. A prior history of inflammation, metabolic disease, or neurotic joints, except for previous treatment with bisphosphonates, steroids, or opioid analgesics.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Affiliated Hospital of Qinghai UniversityXiningQinghaiChina810000

Sponsors and Collaborators

  • Affiliated Hospital of Qinghai University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jiuda Zhao, Professor, Affiliated Hospital of Qinghai University
ClinicalTrials.gov Identifier:
NCT05125432
Other Study ID Numbers:
  • AHQU-2021006
First Posted:
Nov 18, 2021
Last Update Posted:
Nov 18, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jiuda Zhao, Professor, Affiliated Hospital of Qinghai University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2021